HM2: Are expedited programmes delivering on the promise to accelerate drug development and patient access?
By Segolene Saintpierre2022-12-05T00:20:00
Expedited programmes available in the US, Europe and UK all aim to streamline process and ensure early access of medicinal products to patients; however, they are not yet fully delivering on their promises.
This is member-only content
To read this article, SIGN IN NOW if you are a TOPRA member.